GO
| HSI1 | 25,311.21 | -18.52 | 216.69B |
| HSCEI1 | 8,450.10 | -12.54 | 66.58B |
| Back Zoom + Zoom - Block Traded | |
|
CHINARES PHARMA (03320.HK) Unit China Resources Double-Crane's Lomustine Capsules Obtain Drug Registration Certificate
2026-09-02 17:07:05 CHINARES PHARMA (03320.HK) announced that lomustine capsules filed by China Resources Double-Crane, a subsidiary of the group, as the domestic agent, have recently obtained the Drug Registration Certificate issued by the National Medical Products Administration. At the beginning of 2024, China Resources Double-Crane signed a cooperation agreement with Latina Pharma S.P.A to introduce lomustine capsules and act as the exclusive agent in China. The agency term is valid for five years starting from the first commercial sale in the China market. China Resources Double-Crane submitted a marketing authorization application to the National Medical Products Administration on 31 Jan 2024, and received approval for marketing from the regulator on 25 Aug 2026, together with a six-year data protection period. Lomustine capsules are applicable to children and adult patients with primary malignant brain tumors after surgery and/or radiotherapy. (sl/a)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |